154 related articles for article (PubMed ID: 35306156)
1. Tumor budding is an independent prognostic factor in stage III colon cancer patients: a post-hoc analysis of the IDEA-France phase III trial (PRODIGE-GERCOR).
Basile D; Broudin C; Emile JF; Falcoz A; Pagès F; Mineur L; Bennouna J; Louvet C; Artru P; Fratte S; Ghiringhelli F; André T; Derangère V; Vernerey D; Taieb J; Svrcek M;
Ann Oncol; 2022 Jun; 33(6):628-637. PubMed ID: 35306156
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Tumor Budding in Predicting Survival for Gastric Carcinoma Patients in Vietnam.
Dao TV; Nguyen CV; Nguyen QT; Vu HTN; Phung HT; Bui OT; Nguyen DK; Luong BV; Tran TV
Cancer Control; 2020; 27(1):1073274820968883. PubMed ID: 33136444
[TBL] [Abstract][Full Text] [Related]
3. Tumour budding in pancreatic cancer revisited: validation of the ITBCC scoring system.
Karamitopoulou E; Wartenberg M; Zlobec I; Cibin S; Worni M; Gloor B; Lugli A
Histopathology; 2018 Jul; 73(1):137-146. PubMed ID: 29495092
[TBL] [Abstract][Full Text] [Related]
4. Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study.
Pagès F; André T; Taieb J; Vernerey D; Henriques J; Borg C; Marliot F; Ben Jannet R; Louvet C; Mineur L; Bennouna J; Desrame J; Faroux R; Kirilovsky A; Duval A; Laurent-Puig P; Svrcek M; Hermitte F; Catteau A; Galon J; Emile JF
Ann Oncol; 2020 Jul; 31(7):921-929. PubMed ID: 32294529
[TBL] [Abstract][Full Text] [Related]
5. Is there no need to discuss adjuvant chemotherapy in stage II colon cancer patients with high tumor budding and lymphovascular invasion?
Zenger S; Gurbuz B; Can U; Erginoz E; Ozata IH; Yilmaz SP; Taskin OC; Peker O; Adsay V; Balik E; Bugra D
Langenbecks Arch Surg; 2023 Mar; 408(1):127. PubMed ID: 36973561
[TBL] [Abstract][Full Text] [Related]
6. Prognostic and predictive values of tumour budding in stage IV colorectal cancer.
Nagata K; Shinto E; Yamadera M; Shiraishi T; Kajiwara Y; Okamoto K; Mochizuki S; Hase K; Kishi Y; Ueno H
BJS Open; 2020 Aug; 4(4):693-703. PubMed ID: 32472647
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of tumour budding in stomach cancers.
Kucuk S
Int J Clin Pract; 2021 Dec; 75(12):e14922. PubMed ID: 34580963
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Value of Tumor Deposits for Disease-Free Survival in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the IDEA France Phase III Trial (PRODIGE-GERCOR).
Delattre JF; Cohen R; Henriques J; Falcoz A; Emile JF; Fratte S; Chibaudel B; Dauba J; Dupuis O; Bécouarn Y; Bibeau F; Taieb J; Louvet C; Vernerey D; André T; Svrcek M
J Clin Oncol; 2020 May; 38(15):1702-1710. PubMed ID: 32167864
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a
Taieb J; Taly V; Henriques J; Bourreau C; Mineur L; Bennouna J; Desrame J; Louvet C; Lepere C; Mabro M; Egreteau J; Bouche O; Mulot C; Hormigos K; Chaba K; Mazard T; de Gramont A; Vernerey D; André T; Laurent-Puig P
Clin Cancer Res; 2021 Oct; 27(20):5638-5646. PubMed ID: 34083233
[TBL] [Abstract][Full Text] [Related]
10. Validation of the International Tumor Budding Consensus Conference 2016 recommendations on tumor budding in stage I-IV colorectal cancer.
Dawson H; Galuppini F; Träger P; Berger MD; Studer P; Brügger L; Zlobec I; Inderbitzin D; Lugli A
Hum Pathol; 2019 Mar; 85():145-151. PubMed ID: 30428391
[TBL] [Abstract][Full Text] [Related]
11. Prospective Multicenter Study on the Prognostic and Predictive Impact of Tumor Budding in Stage II Colon Cancer: Results From the SACURA Trial.
Ueno H; Ishiguro M; Nakatani E; Ishikawa T; Uetake H; Matsuda C; Nakamoto Y; Kotake M; Kurachi K; Egawa T; Yasumasa K; Murata K; Ikawa O; Shinji S; Murotani K; Matsui S; Teramukai S; Tomita N; Sugihara K;
J Clin Oncol; 2019 Aug; 37(22):1886-1894. PubMed ID: 31180819
[TBL] [Abstract][Full Text] [Related]
12. Tumor budding and poorly-differentiated cluster in prognostication in Stage II colon cancer.
Lee VWK; Chan KF
Pathol Res Pract; 2018 Mar; 214(3):402-407. PubMed ID: 29487008
[TBL] [Abstract][Full Text] [Related]
13. Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer.
Mlecnik B; Bifulco C; Bindea G; Marliot F; Lugli A; Lee JJ; Zlobec I; Rau TT; Berger MD; Nagtegaal ID; Vink-Börger E; Hartmann A; Geppert C; Kolwelter J; Merkel S; Grützmann R; Van den Eynde M; Jouret-Mourin A; Kartheuser A; Léonard D; Remue C; Wang JY; Bavi P; Roehrl MHA; Ohashi PS; Nguyen LT; Han S; MacGregor HL; Hafezi-Bakhtiari S; Wouters BG; Masucci GV; Andersson EK; Zavadova E; Vocka M; Spacek J; Petruzelka L; Konopasek B; Dundr P; Skalova H; Nemejcova K; Botti G; Tatangelo F; Delrio P; Ciliberto G; Maio M; Laghi L; Grizzi F; Fredriksen T; Buttard B; Lafontaine L; Bruni D; Lanzi A; El Sissy C; Haicheur N; Kirilovsky A; Berger A; Lagorce C; Paustian C; Ballesteros-Merino C; Dijkstra J; van de Water C; van Lent-van Vliet S; Knijn N; Muşină AM; Scripcariu DV; Popivanova B; Xu M; Fujita T; Hazama S; Suzuki N; Nagano H; Okuno K; Torigoe T; Sato N; Furuhata T; Takemasa I; Itoh K; Patel PS; Vora HH; Shah B; Patel JB; Rajvik KN; Pandya SJ; Shukla SN; Wang Y; Zhang G; Kawakami Y; Marincola FM; Ascierto PA; Fox BA; Pagès F; Galon J
J Clin Oncol; 2020 Nov; 38(31):3638-3651. PubMed ID: 32897827
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of tumour budding assessed in gastric carcinoma according to the criteria of the International Tumour Budding Consensus Conference.
Ulase D; Heckl S; Behrens HM; Krüger S; Röcken C
Histopathology; 2020 Feb; 76(3):433-446. PubMed ID: 31538348
[TBL] [Abstract][Full Text] [Related]
15. Association of tumor budding with clinicopathological features and prognostic value in stage III-IV colorectal cancer.
Luo YH; Yan ZC; Liu JY; Li XY; Yang M; Fan J; Huang B; Ma CG; Chang XN; Nie X
World J Gastroenterol; 2024 Jan; 30(2):158-169. PubMed ID: 38312121
[TBL] [Abstract][Full Text] [Related]
16. Increasing tumor budding in cholangiocarcinoma is associated with decreased disease-specific survival.
Agostini-Vulaj D; Cates JMM; Bratton LE; Gonzalez RS
Hum Pathol; 2021 May; 111():75-83. PubMed ID: 33727168
[TBL] [Abstract][Full Text] [Related]
17. Refining the ITBCC tumor budding scoring system with a "zero-budding" category in colorectal cancer.
Zlobec I; Bächli M; Galuppini F; Berger MD; Dawson HE; Nagtegaal ID; Lugli A
Virchows Arch; 2021 Dec; 479(6):1085-1090. PubMed ID: 33843013
[TBL] [Abstract][Full Text] [Related]
18. Tumour budding in preoperative biopsy specimens is a useful prognostic index for identifying high-risk patients in early-stage (pN0) colon cancer.
Zengin M; Çifci A
Turk J Med Sci; 2020 Apr; 50(2):375-385. PubMed ID: 32011836
[TBL] [Abstract][Full Text] [Related]
19. No time to die: the consensus immunoscore for predicting survival and response to chemotherapy of locally advanced colon cancer patients in a multicenter international study.
Ascierto PA; Marincola FM; Fox BA; Galon J
Oncoimmunology; 2020 Oct; 9(1):1826132. PubMed ID: 33194317
[TBL] [Abstract][Full Text] [Related]
20. Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status.
Taieb J; Kourie HR; Emile JF; Le Malicot K; Balogoun R; Tabernero J; Mini E; Folprecht G; Van Laethem JL; Mulot C; Bouché O; Aparicio T; Michel P; Thaler J; Bridgewater J; Van Cutsem E; Perkins G; Lepage C; Salazar R; Laurent-Puig P;
JAMA Oncol; 2018 Jul; 4(7):e173695. PubMed ID: 29167892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
